Would you prefer nivolumab/ipilimumab combination over single agent pembrolizumab for a metachronous low volume MSI-H, metastatic colon cancer, with KRAS mutation?
Community PollStarted
What treatment would you offer for a patient with metachronous low volume MSI-high, KRAS mutated metastatic colon cancer?
23 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · City of Hope Orange County
Answered on
To date, I don't think there are any single negative or positive predictive markers of response to immunotherapy in dMMR/MSI-High.
The ones identified retrospectively on subset analyses include
- KRAS as you mentioned
- Other studies with BRAF,
- Or liver metastatic disease
- Elderly
However, my take/experi...
Join for free or sign in to see the full answer